Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

The AHA Nov. 15 filed friend-of-the-court briefs in the U.S. Court of Appeals for the 5th Circuit in support of an earlier ...

The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

Johnson & Johnson and Eli Lilly both sued the federal government this month over the future of their respective 340B drug rebate plans.

Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...

Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...

Johnson and Johnson Nov. 12 filed a lawsuit against the Department of Health and Human Services and the Health Resources and ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...